Introduction
============

The treatment of rheumatoid arthritis (RA) and other immune-mediated diseases has benefited from the development of a variety of tumor necrosis factor-α (TNF-α) inhibitors such as etanercept (ETN), adalimumab (ADA), golimumab (GLM), certolizumab (CZM), and infliximab (INF)[@B1]-[@B6]. These TNF-α inhibitors are effective in reducing the signs and symptoms of RA and in inhibiting structural damage compared to traditional disease-modifying anti-rheumatic drugs[@B7], [@B8]. ETN, ADA, GLM, CZM, and INF are currently available the U.S. Food and Drug Administration (FDA)-approved TNF-α inhibitors[@B1]-[@B6]. They all appear to possess similar efficacy in clinical practice. ETN, ADA, GLM, and CZM are administered subcutaneously (SC) by the patient. INF, on the other hand, is administered intravenously (IV) by a health care professional.

Patient experience with injectable biologics appears to be an important consideration when selecting a TNF-α inhibitor[@B9]. Several studies have found that patients prefer SC injection over IV drug administration and prefer to receive treatment at home[@B10], [@B11]. The adverse events reported in clinical trials of SC TNF-α inhibitors include injection site reactions (ISRs), infections, headaches, etc. ISR, by definition, includes any of the following: erythema, pruritus, pain, inflammation, rash, induration, itching, and edema. The prevalence of these symptoms has been reported as ranging from 12-37% in clinical trials[@B2], [@B3]. Since ISR is often subjective, and may not be a part of routine inquiries by physicians, its prevalence could be underestimated in many rheumatological practices[@B12]. Although SC TNF-α inhibitors may be more convenient than IV infusion, they may induce ISR, which may affect patient quality of life (QoL). ISR gives rise to stress, nervousness, and a reduced QoL. In order to alleviate pain and other symptoms, early countermeasures against this adverse event class must be taken. However, at present, even the prevalence and clinical importance of ISR in routine clinical practice is uncertain[@B13].

The FDA Adverse Event Reporting System (FAERS) is a spontaneous reporting system (SRS) and the largest and best-known database in world. Data collected from doctors, nurses, and other concerned clinical practitioners are compiled in this database. FAERS reflects the realities of clinical practice[@B14]. SRS can be used to evaluate drug-associated adverse events via disproportionality analysis, which usually involves the crude reporting odds ratio (ROR)[@B15]. The crude ROR can be used in a technique that allows for adjustments through logistic regression analyses in order to mitigate the effects of confounding factors[@B16]-[@B22].

To the best of our knowledge, the relationship between SC TNF-α inhibitors and ISR has not yet been evaluated with regards to age-stratified patient groups analyzed from SRS. In this study, we evaluated a possible relationship between SC TNF-α inhibitors and ISR from data available in the FAERS database using a logistic regression model and subset analysis. Furthermore, TNF-α inhibitors are often combined with methotrexate (MTX) in RA treatment[@B7], [@B8]. This combination therapy was found in our study to cause fewer ISR cases than monotherapy using a single TNF-α inhibitor.

Methods
=======

Data from January 2004 to December 2015 present in the FAERS database were downloaded from the FDA website (<http://www.fda.gov/>). The FAERS database structure complies with standards of the International Council on Harmonization (ICH) E2B. DrugBank ver. 3.0 and 4.0 (The Metabolomics Innovation Centre, Canada, <http://www.drugbank.ca/>) were utilized as dictionaries for batch conversion and compilation of drug names[@B23]. We built a database that integrated the FAERS database and DrugBank data using FileMaker Pro 13 software (FileMaker, Inc.). In the FAERS database, adverse events are coded according to the terminology prescribed by the Medical Dictionary for Regulatory Activities (MedDRA) 19.0 (<http://www.meddra.org/>). The preferred terms (PTs) selected for identification of ISR reporting were 77 terms containing the words "injection site" (Table [1](#T1){ref-type="table"}). We followed the FDA\'s recommendation in adopting the most recent case numbers in order to identify duplicate reports from the same patient and exclude them from analysis[@B24]. Additionally, only reports with complete age and sex information were extracted.

From the selected reports, we calculated both the crude ROR and the adjusted ROR. Patients using TNF-α inhibitors were categorized by age (\< 20, 20-29, 30-39, 40-49, 50-59, 60-69, and ≥ 70-year-old groups). Crude ROR was calculated using a two-by-two contingency table in the form of (a\*d)/(b\*c) (Table [2](#T2){ref-type="table"}). A "case" was defined as patients reporting adverse events relating to "ISR", while "non-cases" were defined as patients without adverse events relating to "ISR"[@B24]. RORs were each expressed as a point estimate with 95% confidence intervals (CIs). The safety signal was defined as the lower limit of the 95% CI for each ROR exceeding 1[@B15].

RORs can be adjusted using logistic regression analysis and then used to analyze the effects of interaction terms in detail[@B16]-[@B18], [@B21], [@B22]. The FAERS database included information relating to confounding factors that affect the crude ROR. The logistic model used to calculate the adjusted ROR was as follows:
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(Y = reporting year, S = sex, A = age-stratified group, T = TNF-α inhibitor, M = MTX)

The 20-29-year-old group was used as a reference group to calculate RORs adjusted for age variations. A likelihood ratio test can be used to evaluate the effect of adding a particular term. Because the difference in -2 log-likelihood follows a chi-square distribution with one degree of freedom, adding an interaction term, in this case, was statistically significant (p \< 0.05). These analyses were performed using JMP 11 (SAS Institute Inc., Cary, NC, U.S.A.).

The data subsets strategy may help to mitigate the effect of confounding factors on signal detection by limiting the analysis to a population of patients that are thought to share common risk factors and diseases[@B20], [@B25]-[@B27]. We evaluated the intra-class RORs of the ETN-treatment subset as well as the ADA-treatment subset.

Because the FAERS database does not contain information on the severity of ISR, this information was not taken into account in our analysis.

Results
=======

The FAERS database contains 7,561,254 reports from January 2004 to December 2015. After excluding duplicate reports, 6,157,897 reports remained. Following selection for reports containing sex and age information, a final total of 3,839,264 reports were analyzed in this study. In total, 137,535 reports corresponded to case PTs (Tables [3](#T3){ref-type="table"}, 4). The number of reports of ISRs for ETN, ADA, GLM, CZM, and INF were 57,428, 32,223, 235, 565, and 271, respectively. Since the number of extracted reports of ISRs for GLM and CZM were low, and since INF is an IV-administered TNF-α inhibitor, we did not further investigate reports relating to these drugs. Other biological disease-modifying antirheumatic drugs (DMARDs), abatacept (T-cell action blocker) and tocilizumab (IL-6 inhibitor) were not included in our study.

For ETN, the crude RORs for ISRs stratified by age are summarized in Table [3](#T3){ref-type="table"}. The \< 20, 20-29, 30-39, 40-49, 50-59, 60-69, and ≥ 70-year-old groups contained 6,960, 9,384, 20,665, 37,823, 64,097, 51,481, and 25,737 reports relating to all adverse events, respectively. The \< 20, 20-29, 30-39, 40-49, 50-59, 60-69, and ≥ 70-year-old groups contained 2,300, 3,219, 6,897, 11,314, 17,610, 11,587, and 4,501 reports relating to ISRs, respectively. The crude RORs (95% CIs) were 13.49 (12.83-14.19), 14.37 (13.76-15.00), 14.14 (13.73-14.56), 12.43 (12.15-12.71), 11.55 (11.34-11.76), 8.44 (8.27-8.63), and 5.86 (5.68-6.06), respectively. The adjusted RORs (95% CIs) for interaction terms for ETN\* \< 20, ETN\* 20-29, ETN\* 30-39, ETN\* 40-49, ETN\* 50-59, ETN\* 60-69, and ETN\* ≥ 70-year-old groups were 19.95 (18.86-21.11), 20.48 (19.48-21.52), 19.85 (19.10-20.63), 16.88 (16.32-17.45), 14.78 (14.34-15.24), 11.28 (10.92-11.66), and 8.09 (7.77-8.43), respectively (Table [3](#T3){ref-type="table"}). All interaction terms were statistically significant (p \< 0.0001) (Table [3](#T3){ref-type="table"}). The crude RORs for ISRs in groups stratified based on therapy type are summarized in Table [3](#T3){ref-type="table"}. The adjusted RORs (95% CIs) for ETN monotherapy, MTX monotherapy, and ETN + MTX combination therapy were 20.48 (19.48-21.52), 3.70 (3.60-3.80), and 18.30 (17.29-19.36), respectively.

For ADA, the crude RORs for ISRs stratified by age are summarized in Table [4](#T4){ref-type="table"}. For age-stratified groups, the \< 20, 20-29, 30-39, 40-49, 50-59, 60-69, and ≥ 70-year-old groups contained 6,204, 15,007, 20,422, 28,644, 38,915, 29,453, and 16,059 reports relating to all adverse events, respectively. The \< 20, 20-29, 30-39, 40-49, 50-59, 60-69, and ≥ 70-year-old groups were 1,582, 4,032, 4,904, 6,405, 7,962, 5,178, and 2,160 reports relating to ISRs, respectively. Crude RORs (95% CIs) for each of the same groups were 9.31 (8.79-9.86), 10.16 (9.79-10.53), 8.78 (8.50-9.07), 8.08 (7.86-8.31), 7.29 (7.11-7.47), 5.93 (5.75-6.11), and 4.23 (4.04-4.43), respectively. The adjusted RORs (95% CIs) for interaction terms for ADA\* \< 20, ADA\* 20-29, ADA\* 30-39, ADA\* 40-49, ADA\* 50-59, ADA\* 60-69, and ADA\* ≥ 70-year-old groups were 16.07 (15.08-17.13), 16.18 (15.46-16.92), 13.91 (13.34-14.51), 12.77 (12.29-13.28), 11.30 (10.89-11.73), 9.39 (9.02-9.79), and 6.90 (6.54-7.27), respectively (Table [4](#T4){ref-type="table"}). All interaction terms were statistically significant (p \< 0.0001) (Table [4](#T4){ref-type="table"}). The crude RORs for ISRs in groups stratified based on therapy type are summarized in Table [4](#T4){ref-type="table"}. The adjusted RORs (95% CIs) for ADA monotherapy, MTX monotherapy, and ADA + MTX combination therapy were 16.18 (15.46-16.92), 3.59 (3.50-3.68), and 15.05 (14.24-15.91), respectively.

Discussion
==========

RA is an autoimmune disease and a chronic inflammatory disorder. Despite novel therapies such as TNF-α inhibitors entering the market, RA treatment strategy has generally comprised of case control, pain mitigation, and increasing QoL for patients[@B7], [@B8]. This is largely because ISR has been found to be a relatively common side effect of injectable TNF-α inhibitors[@B28]-[@B31]. ISR usually occurs within the first month of treatment, lasting for 3 to 5 days[@B32]. Although most cases of ISR resolve themselves, symptomatic eruptions are treated with corticosteroids, antihistamines, acetaminophen, or cold compresses[@B32]. The effect of ISR on clinical outcomes for RA is unknown, but research involving multiple sclerosis patients that shows pain during and after injections has been found to affect adherence to drug regimen[@B33]. Side effects such as ISR may similarly be an important factor involved in the patient preference for SC TNF-α inhibitors and treatment adherence.

Our results suggest that ETN and ADA monotherapy does induce ISRs, while MTX combination therapy with ETN or ADA decreases the incidence of this adverse event. Our findings also suggest that aging may influence the adjusted RORs for ETN or ADA therapy based on the logistic regression analysis performed using the FAERS database.

ISR commonly occurs in biologic DMARDs such as TNF-α inhibitors administered via SC injections, and is becoming more clinically important as the number of biologic therapies available for RA therapy increases. ETN and ADA were both found to be associated with ISR in the FAERS database. The adjusted RORs for ADA treatment were lower than those for ETN treatment. ETN was administered to RA patients once or twice per week[@B1], [@B2]. On the other hand, ADA was administered once every two weeks[@B3]. The difference in administration frequency between ETN and ADA may be the cause for the high crude and adjusted RORs for ETN therapy when compared to RORs for ADA therapy (Tables [3](#T3){ref-type="table"}, 4). Perhaps since GLM is a biologic agent which is administered once a month[@B4], the number of reports regarding adverse events induced by GLM was found to be low. Multiple studies of drug adherence across a variety of medications have reported an inverse relationship between dosing frequency and drug adherence[@B34]-[@B36], and patients have been found to prefer longer dosing intervals when given the option[@B37]-[@B39]. Another plausible reason for the differences in RORs is the varying composition of different TNF-α inhibitors, which can range from a complex composition with strong buffering capacity[@B3] to a more simple composition with weak buffering capacity[@B5]. Further work to better understand potential mechanisms of ISR and the consequent clinical implications is needed.

Analysis using a logistic model allows for adjustment of confounding factors included in crude ROR calculation. The 95% CIs lower limits for crude and adjusted RORs for both ETN and ADA therapy were above 1 (Tables [3](#T3){ref-type="table"}, 4, Fig [1](#F1){ref-type="fig"}). Adjusted RORs for ETN\* ≥ 70 and ADA\* ≥ 70 were the lowest in each age-stratified group (Tables [3](#T3){ref-type="table"}, 4, Fig [1](#F1){ref-type="fig"}). Therefore, in our study, we have demonstrated that adjusted RORs decreased with an increase in age.

We do not have a conclusive explanation for these data. To the best of our knowledge, systematic studies of ISR that are stratified by age group are rare. Additionally, the biological mechanisms that mediate ISR by SC TNF-α inhibitors are not well understood. Therefore, ISR may be related to inflammatory mediators that are released during non-immune-stimulated mast cell degranulation[@B40]. Immune function decreases with age owing to the reduced function of T lymphocytes[@B41]. A plausible reason for our result may therefore be related to the differences in sensitivity to medication between younger and older patients.

Regarding effectiveness, several clinical studies have suggested that treatment of RA with TNF-α inhibitor drugs should be in combination with MTX[@B42]-[@B46]. The guidelines also suggest that ETN + MTX combination therapy is more effective than ETN monotherapy[@B7], [@B8]. From the perspective of safety, the reporting ratio of other severe adverse events, such as infection, for ETN + MTX combination therapy is similar to that for ETN monotherapy[@B42]-[@B46]. The adjusted RORs of ISRs for ETN + MTX combination therapy and ADA + MTX combination therapy were lower than those for their respective monotherapies (Tables [3](#T3){ref-type="table"}, 4). Therefore, our result strengthens the credibility of ETN + MTX combination therapy in the clinical setting.

There are several limitations to this study, and the results obtained from SRSs, such as the FAERS database, as well as specifically from our own study, should be interpreted with caution. SRS is a passive reporting system and is therefore subject to biases such as under-reporting, over-reporting, and confounding by comorbidities[@B24]. Most notably, there is a lack of comparison groups as well as missing data relating to patient characteristics[@B15], [@B24]. Cases reported in the FAERS database do not always contain sufficient information regarding patient background, dose response and mode of administration to allow for proper evaluation. For example, it is worthwhile to note that a possible association has been found between a patient\'s mental health and his/her pain sensitivity in context of adverse events. It has been reported that ISR reporting was higher among patients with more severe RA, and also among those with fibromyalgia and depression[@B12], [@B47]. At least 7% of patients develop "recall ISR" or reaction at a prior treatment site following subsequent injections[@B32]. Moreover, patients may not complain about ISR if they perceive it to be a trade-off required to achieve the benefit of these medications. Our analysis also did not evaluate the association between ISR and the duration of therapy with ETN or ADA. We could not incorporate patient prior experiences and information regarding other concurrently administered medications into our analysis.

Because of these limitations, crude RORs without logistic regression analysis do not indicate the risk of adverse event occurrence in absolute terms, and can only offer a rough indication of signal strength[@B15]. For this reason, we partially refined the results with a dedicated correction in order to detect possible confounders present in the database using logistic regression and subset analysis. Consequently, we believe that despite the limitations, it may be acceptable to compare the adjusted RORs of a particular adverse event derived from stratified analysis within a particular context. However, further research is needed in order to more accurately determine the specific associations between TNF-α inhibitors and ISR.

When discussing SC TNF-α inhibitor treatment for RA, ISR may be an important factor for patient comfort and safety as well as therapeutic efficacy. Our results show that younger patients should be closely monitored for ISR when they are administered a SC TNF-α inhibitor. It is important to provide patients with information regarding the tolerability of SC TNF-α inhibitors. We hope that our research may make a valuable contribution to the information available to clinicians in order to improve the management of RA and to allow patients to make a more informed treatment choice.

Conclusions
===========

This study was the first to evaluate the correlation between aging and induction of ISRs by TNF-α inhibitors using SRS analysis strategy. We demonstrated that overall, the adjusted RORs in younger patients were comparatively high. Therefore, we can infer that younger RA patients receiving ETN or ADA treatment should be closely monitored for ISR symptoms. We also provided evidence of higher efficacy of combined therapy comprising ETN and MTX administration. Our results may potentially be used in clinical practice to improve the management of RA and ISRs adverse events.
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###### 

Preferred terms associated with injection site reaction in MedDRA.

  PT^a)^CODE   PT NAME                             PT^a)^ CODE   PT NAME
  ------------ ----------------------------------- ------------- ------------------------------------------
  10022044     injection site abscess              10064111      injection site joint inflammation
  10022045     injection site abscess sterile      10053979      injection site joint movement impairment
  10022046     injection site anaesthesia          10049261      injection site joint pain
  10022048     injection site atrophy              10049260      injection site joint swelling
  10022052     injection site bruising             10049262      injection site joint warmth
  10054812     injection site calcification        10067253      injection site laceration
  10050057     injection site cellulitis           10057665      injection site lymphadenopathy
  10050082     injection site coldness             10067255      injection site macule
  10022055     injection site cyst                 10022081      injection site mass
  10022056     injection site dermatitis           10056250      injection site movement impairment
  10065600     injection site discharge            10022082      injection site necrosis
  10051572     injection site discolouration       10022083      injection site nerve damage
  10054266     injection site discomfort           10057880      injection site nodule
  10067252     injection site dryness              10022085      injection site oedema
  10069124     injection site dysaesthesia         10022086      injection site pain
  10066221     injection site eczema               10066041      injection site pallor
  10022059     injection site erosion              10066044      injection site papule
  10022061     injection site erythema             10022088      injection site paraesthesia
  10068689     injection site exfoliation          10022090      injection site phlebitis
  10022062     injection site extravasation        10053396      injection site photosensitivity reaction
  10022064     injection site fibrosis             10073174      injection site plaque
  10022065     injection site granuloma            10022093      injection site pruritus
  10022066     injection site haematoma            10054994      injection site pustule
  10022067     injection site haemorrhage          10022094      injection site rash
  10073418     injection site hyperaesthesia       10022095      injection site reaction
  10022071     injection site hypersensitivity     10066797      injection site recall reaction
  10075313     injection site hypertrichosis       10066210      injection site scab
  10022072     injection site hypertrophy          10059009      injection site scar
  10074586     injection site hypoaesthesia        10066778      injection site streaking
  10022075     injection site induration           10053425      injection site swelling
  10022076     injection site infection            10022104      injection site thrombosis
  10022078     injection site inflammation         10022105      injection site ulcer
  10066083     injection site injury               10022107      injection site urticaria
  10022079     injection site irritation           10067995      injection site vasculitis
  10048648     injection site ischaemia            10022111      injection site vesicles
  10073459     injection site joint discomfort     10022112      injection site warmth
  10064494     injection site joint effusion       10073752      lack of injection site rotation
  10076327     injection site joint erythema       10025478      malabsorption from injection site
  10064111     injection site joint inflammation                 

a\) Preferred Term

###### 

2×2 contingency table.

                                   Adverse event of interest      All other adverse events of interest      Total
  ----------------------------- -- --------------------------- -- -------------------------------------- -- ---------------
  Drug of interest                 a                              b                                         a + b
                                                                                                            
  All other drugs of interest      c                              d                                         c + d
                                                                                                            
  Total                            a + c                          b + d                                     a + b + c + d

ROR^a)^ = a\*d/b\*c.

95% CI^b)^ = e^ln(ROR)±1.96√(1/a+1/b+1/c+1/d)^.

a\) Reporting Odds Ratio, b) Confidence Interval.

###### 

Crude and Adjusted ROR of etanercept for injection site reaction.

                   Total       Case^a)^   Crude ROR^b)^(95% CI^c)^)   Adjusted ROR^b)^ (95% CI^c)^)   Likelihood ratio test
  ---------------- ----------- ---------- --------------------------- ------------------------------- -----------------------
  Total            3,839,264   137,535                                                                
  Female           2,344,951   108,144    2.41 (2.38-2.44)            1.99 (1.96-2.02)                \<0.0001
  Reporting year                                                      1.02 (1.02-1.02)                \<0.0001
                                                                                                      
  **Age (y.o.)**                                                                                      
  \<20             234,685     5,433      0.62 (0.61-0.64)            0.58 (0.55-0.60)                \<0.0001
  20-29            265,823     9,716      1.02 (1.00-1.04)            1                               
  30-39            367,427     16,538     1.31 (1.28-1.33)            1.11 (1.07-1.14)                \<0.0001
  40-49            534,967     25,776     1.45 (1.43-1.47)            1.18 (1.15-1.22)                \<0.0001
  50-59            773,826     37,337     1.50 (1.48-1.52)            1.13 (1.10-1.16)                \<0.0001
  60-69            775,032     27,157     0.97 (0.96-0.98)            0.89 (0.86-0.91)                \<0.0001
  ≥70              887,504     15,578     0.41 (0.41-0.42)            0.54 (0.52-0.55)                \<0.0001
                                                                                                      
  ETN^d)^          216,147     57,428     16.00 (15.81-16.19)         20.48 (19.48-21.52)             \<0.0001
  MTX^e)^          102,712     12,569     4.03 (3.95-4.11)            3.70 (3.60-3.80)                \<0.0001
  ETN\*MTX         27,451      6,759      9.19 (8.94-9.46)            18.30 (17.29-19.36)             \<0.0001
                                                                                                      
  **ETN\*Age**                                                                                        
  ETN\*\<20        6,960       2,300      13.49 (12.83-14.19)         19.95 (18.86-21.11)             \<0.0001
  ETN\*20-29       9,384       3,219      14.37 (13.76-15.00)         20.48 (19.48-21.52)             \<0.0001
  ETN\*30-39       20,665      6,897      14.14 (13.73-14.56)         19.85 (19.10-20.63)             \<0.0001
  ETN\*40-49       37,823      11,314     12.43 (12.15-12.71)         16.88 (16.32-17.45)             \<0.0001
  ETN\*50-59       64,097      17,610     11.55 (11.34-11.76)         14.78 (14.34-15.24)             \<0.0001
  ETN\*60-69       51,481      11,587     8.44 (8.27-8.63)            11.28 (10.92-11.66)             \<0.0001
  ETN\*≥70         25,737      4,501      5.86 (5.68-6.06)            8.09 (7.77-8.43)                \<0.0001

a\) Number of patients with injection site reaction, b) Reporting Odds Ratio, c) Confidence Interval, d) etanercept, e) methotrexate.

###### 

Crude and Adjusted ROR of adalimumab for injection site reaction.

                   Total       Case^a)^   Crude ROR^b)^(95% CI^c)^)   Adjusted ROR^b)^(95% CI^c)^)   Likelihood ratio test
  ---------------- ----------- ---------- --------------------------- ------------------------------ -----------------------
  Total            3,839,264   137,535                                                               
  Female           2,344,951   108,144    2.41 (2.38-2.44)            2.23 (2.20-2.26)               \<0.0001
  Reporting year                                                      1.06 (1.05-1.06)               \<0.0001
                                                                                                     
  Age (y.o.)                                                                                         
  \<20             234,685     5,433      0.62 (0.61-0.64)            0.81 (0.78-0.85)               \<0.0001
  20-29            265,823     9,716      1.02 (1.00-1.04)            1                              
  30-39            367,427     16,538     1.31 (1.28-1.33)            1.51 (1.46-1.56)               \<0.0001
  40-49            534,967     25,776     1.45 (1.43-1.47)            1.77 (1.71-1.82)               \<0.0001
  50-59            773,826     37,337     1.50 (1.48-1.52)            1.85 (1.79-1.90)               \<0.0001
  60-69            775,032     27,157     0.97 (0.96-0.98)            1.37 (1.33-1.41)               \<0.0001
  ≥70              887,504     15,578     0.41 (0.41-0.42)            0.72 (0.70-0.75)               \<0.0001
                                                                                                     
  ADA^d)^          154,704     32,223     8.94 (8.82-9.07)            16.18 (15.46-16.92)            \<0.0001
  MTX^e)^          102,712     12,569     4.03 (3.95-4.11)            3.59 (3.50-3.68)               \<0.0001
  ADA\*MTX         26,441      5,048      6.55 (6.35-6.76)            15.05 (14.24-15.91)            \<0.0001
                                                                                                     
  ADA\*Age                                                                                           
  ADA\*\<20        6,204       1,582      9.31 (8.79-9.86)            16.07 (15.08-17.13)            \<0.0001
  ADA\*20-29       15,007      4,032      10.16 (9.79-10.53)          16.18 (15.46-16.92)            \<0.0001
  ADA\*30-39       20,422      4,904      8.78 (8.50-9.07)            13.91 (13.34-14.51)            \<0.0001
  ADA\*40-49       28,644      6,405      8.08 (7.86-8.31)            12.77 (12.29-13.28)            \<0.0001
  ADA\*50-59       38,915      7,962      7.29 (7.11-7.47)            11.30 (10.89-11.73)            \<0.0001
  ADA\*60-69       29,453      5,178      5.93 (5.75-6.11)            9.39 (9.02-9.79)               \<0.0001
  ADA\*≥70         16,059      2,160      4.23 (4.04-4.43)            6.90 (6.54-7.27)               \<0.0001

a\) Number of patients with injection site reaction, b) Reporting Odds Ratio, c) Confidence Interval, d) adalimumab, e) methotrexate.
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